Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutioni...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Vida, Alejo, Galazi, Myria, Rudman, Sarah, Chowdhury, Simon, Sternberg, Cora N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492664/
https://www.ncbi.nlm.nih.gov/pubmed/26170619
http://dx.doi.org/10.2147/DDDT.S69433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492664/
https://www.ncbi.nlm.nih.gov/pubmed/26170619
http://dx.doi.org/10.2147/DDDT.S69433

Ejemplares similares